Walgreens profit beats on higher demand for prescription drugs

Reuters 

(Reuters) - Boots Alliance Inc reported a quarterly profit that beat analysts' estimates on Thursday, as more people bought prescription drugs from its U.S. and the company benefited from its acquisition of stores.

bought 1,932 stores last year to widen its footprint in the and give it more heft to bargain better on price with drugmakers.

The company also forecast 2019 adjusted profit of $6.40 to $6.70 per share, while analysts are expecting $6.45 per share, according to Thomson I/B/E/S.

Net income attributable to Walgreens, which was added to the Dow Jones Industrial Average index earlier this year, rose to $1.51 billion, or $1.55 per share, in the fourth quarter ended Aug. 31 from $802 million, or 76 cents per share, a year earlier.

Sales at Walgreens' U.S. rose 16.7 percent in the fourth quarter, after the company filled 279.8 million prescriptions.

Same-store sales at its rose 1.3 percent, beating analysts expectations for a 0.57 percent rise, according to eight analysts polled by Thomson I/B/E/S.

Excluding items, the company earned $1.48 per share, beating analysts' expectations of $1.45 per share. Revenue rose 10.9 percent to $33.44 billion.

(Reporting by and in Bengaluru; Editing by Anil D'Silva)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, October 11 2018. 16:58 IST